Campto irinotecan data

RPR (Collegeville, Penn.) reported an 18 percent overall response rate in a Phase II trial in France.

As presented at the European Congress for Clinical Oncology in Paris, a 350 mg/m2 infusion every three weeks gave at least a 50 percent reduction in measurable tumors in 28 patients. ...